Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04094-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Jiahong Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Shang …. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Brachytherapy, Neoplasm Recurrence, Local, Tomography, X-Ray Computed. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Zhejiang Province Public Welfare Technology Application Research Project of China, National Natural Science Foundation of China, Key Project of Zhejiang Provincial Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Permanent radioactive Iodine-125 seed implantation (RISI) is a minimally invasive internal radiation technique that effectively kills tumor cells. This study aimed to investigate the local efficacy and safety of RISI in the treatment of recurrent malignant tumors and to analyze the prognostic factors. METHODS: We retrospectively evaluated 162 patients with recurrent malignant tumors who received RISI in Zhejiang Provincial People's Hospital during January 2020 to December 2022. Local control time (LCT), tumor response, particle implantation site, tumor size, needle number, particle activity, particle number, dose parameters, and adverse reactions were analyzed. RESULTS: With a median follow-up of 14 months, the complete response (CR) rate was 17.9%, partial response (PR) 45.1%, stable disease (SD) 27.8%, and progressive disease (PD) 9.2% in all patients. The median LCT of patients with head and neck metastasis, chest metastasis, abdominal pelvis metastasis, and para-bone metastasis was 11.0, 11.5, 8, and 13 months, while median overall survival (OS) was 11, 11.5, 8, and 13 months, respectively. Univariate analysis showed that tumor size, postoperative D90 dose, and postoperative D100 dose were factors affecting LCT. Smaller tumor size and higher dose level at the implant site contributed to the significantly longer LCT. The dosimetry results showed that D90, D100, V100, V150, and V200 were consistent before and after the operation. In terms of adverse reactions, except for 5 patients with mild pneumothorax, no other serious adverse reactions were reported. CONCLUSIONS: The application of CT-guided Iodine-125 implantation in the treatment of patients with advanced malignant tumors demonstrates favorable clinical efficacy, achieving a high rate of LCT while maintaining a superior level of safety and minimal postoperative adverse reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Shang Tang Road 158, Hangzhou, Zhejiang, 310014, People's Republic of China.
- Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Shang Tang Road 158, Hangzhou, Zhejiang, 310014, People's Republic of Chin…
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Shang Tang Road 158, Hangzhou, Zhejiang, 310014, People's Republic of China.…
Förderung
- Zhejiang Province Public Welfare Technology Application Research Project of China
- National Natural Science Foundation of China
- Key Project of Zhejiang Provincial Natural Science Foundation
- Key Project of Health Bureau of Zhejiang Province
- Basic Scientific Research Funds of Department of Education of Zhejiang Province
Zitieren
APA
Jiang, J., Liu, Q., Zhan, L., Wu, S., Luo, L., Bi, A., Jia, Y., & Yang, L. (2025). Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04094-7
Vancouver
Jiang J, Liu Q, Zhan L, Wu S, Luo L, Bi A, et al. Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04094-7
BibTeX
@article{Jiang2025,
author = {Jiang, Jiahong and Liu, Qian and Zhan, Luying and Wu, Shuqiang and Luo, Limin and Bi, Aihong and Jia, Yongshi and Yang, Liu},
title = {Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04094-7}
}
EUVIMED